Session » Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: II

Meeting: 2013 ACR/ARHP Annual Meeting

Abstract Number: 1505

Evaluation Of a Case Ascertainment Tool For Ankylosing Spondylitis and Axial Spondylarthritis Among All Referrals To General Rheumatology Clinics

Abstract Number: 1506

Total Hip Replacement Outcomes in Ankylosing Spondylitis

Abstract Number: 1507

Infection Risk in Ankylosing Spondylitis: Results From a Longitudinal Observational Cohort

Abstract Number: 1508

How Well Are The Assessment Of Spondyloarthritis International Society (ASAS) / Outcome Measures In Rheumatology (OMERACT) Core Outcome Sets For Ankylosing Spondylitis Implemented In Randomized Clinical Trials? A Systematic Literature Review

Abstract Number: 1509

Immunogenicity, Adalimumab Levels and Clinical Response In Ankylosing Spondylitis Patients During 24 Weeks Of Follow-Up

Abstract Number: 1510

Disease Activity In Male Smokers Has A >10-Fold Amplified Effect On Radiographic Damage In Comparison With Female NON-Smokers In Ankylosing Spondylitis

Abstract Number: 1511

What Impairs Balance In Ankylosing Spondylitis? Posture Or Disease Activity?

Abstract Number: 1512

Smoking and Its Relationship With Clinical, Radiological and Functional Status In Patients With Ankylosing Spondylitis

Abstract Number: 1514

Drug Survival In Patients Receiving Golimumab Treatment 2010-2013. Results From The Swedish Rheumatology Quality Register

Abstract Number: 1515

Influence Of Taking Structural Lesions Into Account In Addition To Inflammatory Lesions On MRI Of The Sacroiliac Joints On The Classification Of Patients With Possible Axial Spondyloarthritis

Abstract Number: 1516

Safety and Efficacy Of Etanercept In Early Non-Radiographic Axial Spondyloarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial At 24 Weeks

Abstract Number: 1517

Different Imaging Abnormalities Suggestive Of Spondyloarthritis Are Present In Early Axial Spondyloarthritis. Data From The DESIR Cohort

Abstract Number: 1518

Prevalence Of Spondylarthritis In Individuals Needing To Purchase An Orthopedic Mattress Because Of Chronic Back Pain

Abstract Number: 1519

Meeting The ACR 2010 Fibromyalgia Criteria Worsens Disease Activity and Quality Of Life In Patients With Axial Spondyloarthritis Treated With Infliximab

Abstract Number: 1520

Reduction Of Disease Burden On Workplace and Household Productivity In Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis, Over 48 Weeks Of Treatment With Certolizumab Pegol

Abstract Number: 1521

Latent Tuberculosis Screening and Treatment In Ankylosing Spondylitis Patients Eligible For Anti-TNF Therapy In Endemic Area

Abstract Number: 1522

Remission In Spondyloarthritis : ASDAS and Basdai Thresholds From a Prospective Real Life Study

Abstract Number: 1523

Presence Of Peripheral Arthritis Delays Spinal Radiographic Progression In Ankylosing Spondylitis: Observation Study Of Korean Spondyloarthropathy Registry (OSKAR) Over 5 Years

Abstract Number: 1525

Measurement Of Lateral Spinal Flexion and Schober Is Sufficient To Be Informed About Spinal Mobility In Patients With Ankylosing Spondylitis: 12-Year OASIS Results

Abstract Number: 1526

Stable Clinical and MRI Response In Patients With Early Axial Spondyloarthritis After 3 Years Of Continuous Treatment With Etanercept, Data Of The Esther Trial

Abstract Number: 1527

Routine Assessment Of Patient Index Data 3 Scores Correlate Well With Bath Ankylosing Spondylitis Disease Activity Index In The Assessment Of Disease Activity and Monitoring Progression Of Ankylosing Spondylitis

Abstract Number: 1528

Patient-Tailored Dose Reduction Of Tumor Necrosis Factor-Alpha Blocking Agents In Ankylosing Spondylitis Patients With Stable Low Disease Activity

Abstract Number: 1529

Patients With Imaging Abnormalities Of The Sacroiliac Joints Are More Likely To Respond To TNF Alpha Inhibitors In Early Axial Spondyloarthritis. Data From The DESIR Cohort

Abstract Number: 1530

Vitamin D Deficiency Is Associated With a More Active and Severe Disease In Early Axial Spondyloarthritis: Data From The DESIR Cohort

Abstract Number: 1531

Agreement Between Disease Activity States and Improvement Scores As Defined by Bath Ankylosing Spondylitis Disease Activity Index and Ankylosing Spondylitis Disease Activity Score Cut-Off Values

Abstract Number: 1532

Anti-Tumor Necrosis Fator Therapy Is Associated With Resolution Of Erosion In The Sacroiliac Joints Of Patients With Spondyloarthritis

Abstract Number: 1533

Work Outcome In Patients With Ankylosing Spondylitis: 12-Year Results From OASIS

Abstract Number: 1534

Safety and Efficacy Of Golimumab, a Human Anti-Tumor Necrosis Factor Monoclonal Antibody Injected Subcutaneously Every 4 Weeks, In Chinese Patients With Active Ankylosing Spondylitis: 1-Year Results Of a Phase 3, Randomized, Placebo-Controlled Study

Abstract Number: 1535

Phenotype Of Patients and Impact Of The Disease In Early Spondyloarthritis Are Similar Regardless The Arm Of The Assessment In Spondyloarthritis International Society Criteria (“imaging” or “clinical”) Fulfilled By The Patients. Data From The DESIR Cohort

Abstract Number: 1536

Do Patients With Ankylosing Spondylitis Have An Excess Prevalence Of Chronic Widespread PAIN?: Results From The Scotland and Ireland Registry For Ankylosing Spondylitis (SIRAS) and The Musician Study

Abstract Number: 1537

Primary & Subsequent Orthopedic Surgeries More Common In Juvenile Vs. Adult-Onset Ankylosing Spondylitis

Abstract Number: 1538

The Age At Onset Of Symptoms Influence The Clinical Expression Of The Disease In Patients With Ankylosing Spondylitis

Abstract Number: 1539

Inflammation In The Posterior Elements Of The Spine Is Infrequent In Patients With Recent Onset Axial Spondyloarthritis, Especially If No Inflammation In The Vertebral Bodies Is Observed

Abstract Number: 1540

Sustained Clinical Remission In Patients With Non-Radiographic Axial Spondyloarthritis After Two Years Of Adalimumab Treatment

Abstract Number: 1541

Spinal Mobility Gets Impaired In a Fixed Order In Patients With Ankylosing Spondylitis: 12-Year OASIS Results

Abstract Number: 1542

Regular Exercise Is Associated With Better Functional Outcomes In Ankylosing Spondylitis

Abstract Number: 1543

Patients With Ankylosing Spondylitis Are Substantially Undertreated For Hypertension and Hypercholesterolemia

Abstract Number: 1544

Good Agreement Between The Ankylosing Spondylitis Disease Activity Scores Based On C-Reactive Protein and Erythrocyte Sedimentation Rate

Abstract Number: 1545

Serum Periostin: a New Marker Of Local Bone Formation In Early Inflammatory Back Pain: results From The DESIR Cohort

Abstract Number: 1546

Patient-Reported Outcomes of Etanercept in Early Non-Radiographic Axial Spondyloarthritis: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Abstract Number: 1547

How The Delay In Diagnosis Impacts On The Clinical, Functional and Radiographic Status Of Patients With Ankylosing Spondylitis. Is There a Window Of Opportunity?

Abstract Number: 1548

Effect Of TNF Inhibitors On Bone Mineral Density In Patients With Ankylosing Spondylitis- a Systematic Review and Meta-Analysis

Abstract Number: 1549

Prevalence Of Syndesmophytes In Patients With Chronic Back Pain Suspected Of Axial Spondyloarthritis (axSpA) Not Fulfilling The Modified New York (mNY) Criteria

Abstract Number: 1550

Validation Of The Ankylosing Spondylitis Disease Activity Score and Effectiveness Of Infliximab In The Treatment Of Ankylosing Spondylitis Over 4 Years: The Canadian Experience

Abstract Number: 1551

The Minimum Clinically Important Improvement and Patient Acceptable Symptom State In Basdai and BASFI For Patients With Ankylosing Spondylitis

Abstract Number: 1552

Effective Prevention Of New Osteitis On Magnetic Resonance Imaging In Patients With Early Axial Spondyloarthritis During 3 Years Of Continous Treatment With Etanercept – Data Of The Esther Trial

Abstract Number: 1553

Responsiveness Of Health Related Quality Of Life Questionnaires To Treatment With Anti-TNF Therapy In Psoriatic Arthritis

Abstract Number: 1554

Real-World Effectiveness Of Infliximab In The Treatment Of Psoriatic Arthritis Over 12 Months: The Canadian Experience

Abstract Number: 1555

Anti-TNF Drug Survival In Psoriatic Arthritis Patients Treated In Ordinary Clinical Practice

Abstract Number: 1556

Paradoxical Psoriasis: Experience Of a Biological Therapy Monographic Unit

Abstract Number: 1557

Assessing The Real Life Impact Of Psoriatic Arthritis On Disability, Quality Of Life, and Provider Satisfaction

Abstract Number: 1558

Drug Trends In Psoriatic Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.